Citius Pharmaceuticals Inc. Common
Symbol: CTXR (NASDAQ)
Company Description:
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
- Today's Open: $0.8449
- Today's High: $0.967
- Today's Low: $0.83
- Today's Volume: 497.76K
- Yesterday Close: $0.8533
- Yesterday High: $0.8549
- Yesterday Low: $0.77
- Yesterday Volume: 574.16K
- Last Min Volume: 570
- Last Min High: $0.911
- Last Min Low: $0.901
- Last Min VWAP: $0.90416
- Name: Citius Pharmaceuticals Inc. Common
- Website: https://www.citiuspharma.com
- Listed Date: 2011-10-18
- Location: CRANFORD, NJ
- Market Status: Active
- CIK Number: 0001506251
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $10.94M
- Round Lot: 100
- Outstanding Shares: 10.83M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-06-12 | 8-K | View |
2025-06-11 | 424B5 | View |
2025-06-09 | 8-K | View |
2025-06-03 | 8-K | View |
2025-05-30 | 8-K | View |
2025-05-14 | 10-Q | View |
2025-05-14 | 8-K | View |
2025-04-28 | DEFA14A | View |
2025-04-28 | DEF 14A | View |
2025-04-18 | PRE 14A | View |
2025-04-18 | 8-K | View |
2025-04-03 | 8-K | View |
2025-04-02 | 8-K | View |
2025-04-02 | 424B5 | View |
2025-03-10 | 8-K | View |
2025-02-14 | 8-K | View |
2025-02-14 | 10-Q | View |
2025-02-06 | 8-K | View |
2025-01-27 | 10-K/A | View |
2025-01-27 | ARS | View |